TY - JOUR
T1 - Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
AU - Giachelia, Manuela
AU - Voso, Maria Teresa
AU - Tisi, Maria Chiara
AU - Martini, Marco
AU - Bozzoli, Valentina
AU - Massini, Giuseppina
AU - D'Alo', Francesco
AU - Larocca, Luigi Maria
AU - Leone, Giuseppe
AU - Hohaus, Stefan
PY - 2012
Y1 - 2012
N2 - Peripheral blood cytokines are known prognostic parameters in diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy, but their role after the introduction of rituximab is unknown. Seven polymorphisms in the promoter regions of IL-6, IL-10 and NF-κB1 genes were assessed in 167 patients with DLBCL and 99 controls and correlated with interleukin-6 (IL-6) and IL-10 plasma levels. Outcome was analyzed in 137 patients treated with rituximab-based chemotherapy. The NF-κB1 - 94ATTG deletion was associated with increased IL-6 and IL-10 in DLBCL. High IL-6 concentration correlated with unfavorable prognostic factors included in the international prognostic index (IPI) and predicted for inferior progression-free (p = 0.007) and overall survival (p = 0.02). IL-6 levels remained a significant outcome predictor also including IPI as a covariate (p = 0.006 for progression-free survival). Our data suggest that the NF-κB1 genetic background influences IL-6 production in DLBCL, and that high IL-6 concentration is an independent prognostic factor also in the "rituximab era."
AB - Peripheral blood cytokines are known prognostic parameters in diffuse large B-cell lymphoma (DLBCL) treated with chemotherapy, but their role after the introduction of rituximab is unknown. Seven polymorphisms in the promoter regions of IL-6, IL-10 and NF-κB1 genes were assessed in 167 patients with DLBCL and 99 controls and correlated with interleukin-6 (IL-6) and IL-10 plasma levels. Outcome was analyzed in 137 patients treated with rituximab-based chemotherapy. The NF-κB1 - 94ATTG deletion was associated with increased IL-6 and IL-10 in DLBCL. High IL-6 concentration correlated with unfavorable prognostic factors included in the international prognostic index (IPI) and predicted for inferior progression-free (p = 0.007) and overall survival (p = 0.02). IL-6 levels remained a significant outcome predictor also including IPI as a covariate (p = 0.006 for progression-free survival). Our data suggest that the NF-κB1 genetic background influences IL-6 production in DLBCL, and that high IL-6 concentration is an independent prognostic factor also in the "rituximab era."
KW - Interleukin-6
KW - Non-Hodgkin lymphoma
KW - Interleukin-6
KW - Non-Hodgkin lymphoma
UR - https://publicatt.unicatt.it/handle/10807/12175
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84856569819&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84856569819&origin=inward
U2 - 10.3109/10428194.2011.621566
DO - 10.3109/10428194.2011.621566
M3 - Article
SN - 1042-8194
VL - 2012
SP - 411
EP - 416
JO - LEUKEMIA & LYMPHOMA
JF - LEUKEMIA & LYMPHOMA
IS - Marzo
ER -